Teva (TEVA) volatility increases after Berkshire Hathaway (BRK.A) disclosed a stake in the company
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
The Oracle of Omaha Goes Value Shopping in the Value Pharmaceutical Bin with Teva (TEVA)
February 15, 2018 12:26 PM ESTWith countless missteps, U.S. generics business weakness, Copaxone generic competition, and an ongoing restructuring, Teva Pharma (NYSE: TEVA) has been labeled your classic "dog" stock for the past couple of years. That all changed yesterday when Warren Buffett's Berkshire Hathaway shocked Wall Street by disclosing in their December-quarter 13F that they had accumulated a new, nearly 19 million share position in the Isreal-based pharmaceutical company.
While it is unclear if the Oracle himself pulled the trigger on the trade, all of Berkshire's lieutenants try to stick to... More
